News

Top line data from this trial, being conducted in Italy, Israel, Greece and Turkey, is expected in Q4 2018. The primary objective of this multi-centre, multi-country and dose-ranging

These are the first data to demonstrate the potential to treat the underlying cause of CF in these patients, who have a severe and difficult-to-treat type of the

Dharmacon, which manufactures RNAi products, has a portfolio of gene editing products, particularly in CRISPR reagents and arrayed libraries. It had generated revenues of $36.7m in 2016 with an EBITDA of $5.4m.

Raxibacumab is a fully human monoclonal antibody, which secured approval from the US Food and Drug Administration (FDA) for the treatment and prophylaxis of inhalational anthrax due to

One of the important non-motor features of Parkinson’s disease is often the early presentation of severe and disabling impairment of gastrointestinal function. Parkinson’s disease is characterised by the

The two companies have also entered into a license agreement which gives the global exclusive rights of BioMarin's DMD patent estate to Sarepta Therapeutics for $35m. Sarepta will

The approval was granted for Vosevi (sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100 mg) tablets, which is a single-tablet regimen to re-treat chronic HCV infection in adults. The approval

The label update is based on results from the ENSURE-AF study, the largest, prospective randomised clinical trial of an anticoagulant for cardioversion in patients with NVAF. The study

Limited partners of the Fund include industry veterans in other geographic markets, such as China Regenerative Medicine International Limited. "The sale of Obagi marks additional progress in our